Checkpoint Therapeutics, Inc. CKPT
4.26 0.00 (+0.00%)
At closeMay 30, 2025, 4:00 PM EDT
4.24 Day range 4.26
52-week range unavailable
- YTD
- +33.12%
- 1 year
- +132.79%
News
globenewswire.com Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
businesswire.com CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
globenewswire.com Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and…
businesswire.com CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of…
globenewswire.com SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options PHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced buyout of Checkpoint Therapeutics, Inc. (“Checkpoint”)…
prnewswire.com CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma NEW YORK , March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun…
proactiveinvestors.com Checkpoint Therapeutics shares pop on acquisition by Sun Pharma Checkpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries. Under the…
benzinga.com Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher 
benzinga.com Nasdaq Dips Over 3%; Checkpoint Therapeutics Shares Jump 
benzinga.com US Stocks Likely To Open Lower After Trump Hints At Looming Recession: Expert Says Can't Rule Out A Bear Market As Indices Inch Towards Correction Territory U.S. stock futures declined on Monday after a small bout of relief on Friday as indices neared the correction zone.
benzinga.com Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket 
businesswire.com Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma. Click…
prnewswire.com Sun Pharma to Acquire Checkpoint Therapeutics Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global…
seekingalpha.com Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval Checkpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor…
globenewswire.com Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous…
seekingalpha.com Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date Checkpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th…
globenewswire.com Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates Biologics License Application for cosibelimab under review by U.S. FDA PDUFA goal date of December 28, 2024 WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc.…
globenewswire.com Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December 28, 2024 Biologics License Application currently under review by U.S. FDA; PDUFA goal date of December…
globenewswire.com Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference WALTHAM, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that…
seekingalpha.com Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual…
zacks.com What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock Checkpoint Therapeutics (CKPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
globenewswire.com Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial…
globenewswire.com Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma WALTHAM, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the…
globenewswire.com GC Cell and Checkpoint Therapeutics Advance Collaborative Cancer Research YONGIN, South Korea and WALTHAM, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- GC Cell (KRX: 144510.KS) and Checkpoint Therapeutics ("Checkpoint") (Nasdaq: CKPT) have announced a collaboration to explore…
benzinga.com Why Compugen Shares Are Trading Higher By Over 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy…
benzinga.com Why Lantheus Holdings Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline results from the pivotal phase 3 SPLASH study in…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 386 stocks made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Kura Sushi Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 104% to $5.55 after the company announced it has been selected by the U.S. Department of Defense for a position on the multiple award Indefinite…- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 93 stocks made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 479 stocks made new 52-week lows.- benzinga.com Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+…
- benzinga.com Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough…
- benzinga.com Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 413 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 446 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 807 companies reached new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 721 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 242 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 466 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday's session saw 729 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 524 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 368 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.